A publication dated October 11, 2026 describes the development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists, including survodutide. The study, titled "Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application," appears in the Journal of Chromatography A.
Survodutide remains an unapproved compound currently in research use. The publication is listed under PubMed ID 42603384.
This entry represents a new addition to the scientific literature concerning analytical methodology for detecting and quantifying GLP-1 receptor agonists in pharmaceutical applications. The publication data provided does not include specific findings, results, or performance metrics for the method as applied to survodutide or the other compounds studied.
No information beyond the title, journal, and publication date has been made available for this brief. Readers interested in the broader context of survodutide, including its regulatory status and research background, can consult the compound overview for additional information.